Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Research finds novel chemical that targets drug-resistant bacteria

Eric Brown, a professor and chair of the Department of Biochemistry and Biomedical Sciences, and a team of researchers from the Michael G. DeGroote Institute for Infectious Disease Research have identified a novel chemical compound that targets drug-resistant bacteria in a different way from existing antibiotics. The discovery could lead to new treatments to overcome antibiotic resistance in certain types of microorganisms.

29 Sep 2009

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has received patent protection for certain exclusively licensed intellectual property by the issuance to the University of Pennsylvania of U.S. patent number 7,590,517, “Methods, Systems, and Computer Program Products for Computational Design of Amphiphilic Polymers.”

28 Sep 2009

European Commission grants conditional marketing authorization for Gilead's Cayston

Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.

28 Sep 2009

Neogen announces first-quarter results of fiscal 2010

Neogen Corporation announced today that its revenues for the first quarter of FY 2010, which ended Aug. 31, increased 12% from the previous year's first quarter to $32,347,000. First quarter net income increased 18% from the prior year's $3,733,000 to $4,395,000, or to $0.29 per share in the current year compared to the previous year's $0.25.

25 Sep 2009

Clostridium difficile's five genetic regions identified

Five genetic regions have been identified that are unique to the most virulent strain of Clostridium difficile (C. difficile), the hospital superbug. Researchers writing in BioMed Central's open access journal Genome Biology studied the genome of the bacterium, looking for genes relating to motility, antibiotic resistance and toxicity.

25 Sep 2009

Mandell, Douglas, and Bennett's publication on infectious diseases released

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the release of Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th Edition. Marking 30 years since its initial publication, it remains the most respected reference source of its kind, and maintains its relevance in the face of the emergence of newly recognized infectious diseases, including new strains of the swine (H1N1) and avian influenza viruses.

24 Sep 2009

Biochemists are developing a new system to better understand antibiotic resistance

Rice University biochemists are developing a system of "evolutionary forecasting" to better understand the mechanisms of antibiotic resistance.

22 Sep 2009

New vaccine may prove effective against urinary tract infections

University of Michigan scientists have made an important step toward what could become the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans.

18 Sep 2009

Book on the effects of antibiotic-resistant microbes

In RISING PLAGUE: THE GLOBAL THREAT FROM DEADLY BACTERIA AND OUR DWINDLING ARSENAL TO FIGHT THEM (Prometheus Books, $26), Dr. Brad Spellberg-an infectious diseases specialist and member of a national task force charged with attacking antibiotic resistant infections-tells the story of this potentially grave public health crisis.

18 Sep 2009

OCLS' partnership with V&M Industries to market Microcyn-based skin and wound care products

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat infections in chronic and acute wounds, announced today it has entered into a new strategic partnership with V&M Industries, Inc. for non-exclusive rights to market Microcyn-based skin and wound care over-the-counter products in the United States and Canada while providing Oculus with a significant percentage of those revenues.

16 Sep 2009

Nomir publishes efficacy of the Noveondual-wavelength device against infectious disease pathogens

Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today the publication of a scientific paper in the journal Photochemistry and Photobiology that details in vitro and human data demonstrating the unique and patented mechanism-of-action for its Noveon® dual-wavelength device, as well as positive efficacy and safety data.

16 Sep 2009

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria.

16 Sep 2009

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

16 Sep 2009

FDA grants orphan drug status to Advanced Life Sciences' Restanza

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.

16 Sep 2009

Antibiotics sold online without prescriptions, according to MUSC researchers

According to MUSC researchers, antibiotics are widely available for purchase on the Internet without a prescription, despite efforts to control antibiotic-resistant bacteria as a result of misuse of these drugs.

15 Sep 2009

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

Rib-X and NIAID collaborate to develop an antibiotic treatment for N. gonorrhoeae

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that it intends to enter into a Clinical Trials Agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services.

15 Sep 2009

Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis

New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.'s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back (lumbar spine) bone mineral density (BMD) were reversed over the next year, while BMD at the hip (femoral neck) remained above levels observed at the start of the study.

15 Sep 2009

Phase 2b trial of Mpex's Aeroquin with PARI Pharma's eFlow Nebulizer System successful

Mpex Pharmaceuticals, Inc. reported positive top line results from a Phase 2b clinical trial with Aeroquin, a novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow Nebulizer System from PARI Pharma. In the Mpex cystic fibrosis trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa in sputum after 28 days of dosing versus placebo.

15 Sep 2009

Environmental Solutions International introduces unique, alcohol-free, moisturizing hand sanitizers

With health officials nationwide already preparing for the upcoming cold and flu season, Environmental Solutions International (ESI) introduces Smart & Silky and Kids Smart & Silky Foaming Hand Sanitizers as another weapon in the illness-prevention arsenal. These unique, alcohol-free, moisturizing hand sanitizers are available at retailers nationwide (visit www.smartandsilky.com for more details).

15 Sep 2009

Antibiotic News and Research

Further Reading

Research finds novel chemical that targets drug-resistant bacteria

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

European Commission grants conditional marketing authorization for Gilead's Cayston

Neogen announces first-quarter results of fiscal 2010

Clostridium difficile's five genetic regions identified

Mandell, Douglas, and Bennett's publication on infectious diseases released

Biochemists are developing a new system to better understand antibiotic resistance

New vaccine may prove effective against urinary tract infections

Book on the effects of antibiotic-resistant microbes

OCLS' partnership with V&M Industries to market Microcyn-based skin and wound care products

Nomir publishes efficacy of the Noveondual-wavelength device against infectious disease pathogens

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

FDA grants orphan drug status to Advanced Life Sciences' Restanza

Antibiotics sold online without prescriptions, according to MUSC researchers

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

Rib-X and NIAID collaborate to develop an antibiotic treatment for N. gonorrhoeae

Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis

Phase 2b trial of Mpex's Aeroquin with PARI Pharma's eFlow Nebulizer System successful

Environmental Solutions International introduces unique, alcohol-free, moisturizing hand sanitizers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News